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Abstract 
 
Primary spinal cord injury (SCI) results from direct mechanical damage to the 
spinal cord.  The resulting pathochemical and pathophysiological events, including 
oxidative stress and inflammation, lead to secondary injury.  The ability to decrease 
secondary injury may lead to improved recovery.  Increasing glutathione production 
after SCI leads to decreased secondary injury.  Glutamine is an important precursor to 
glutathione following trauma.  Skeletal muscle phenotype is strongly influenced by 
neuromuscular activity.  SCI causes myosin heavy chain (MyHC) profiles to shift 
towards faster isoforms in slow muscles and slower isoforms in fast muscles.  The 
hypothesis was that glutamine, as a precursor of glutathione, administration to SCI rats 
would lead to better functional recovery and a more preserved MyHC phenotype in 
locomotory muscles. 
Rats were assigned to one of four groups; healthy, laminectomy only, untreated 
SCI, and SCI treated with an intraperitoneal injection of 1mmol/kg glutamine every 12 
hours for one week after injury.  SCIs were perfomed at T6 with a modified aneurism 
clip.  Functional recovery was measured weekly using the Basso-Beattie-Bresnahan 
scale and the angle board method.  Six weeks later, all rats were killed, and their 
extensor digitorum longus and soleus muscles excised and weighed.  MyHC 
composition of the muscles was determined using SDS-PAGE. 
The hypothesis that glutamine treatment following SCI would lead to better 
functional recovery and a more preserved MyHC profile was validated. Glutamine 
treated rats received significantly higher BBB scores (p<0.01) and angle board scores 
(p<0.001) than untreated SCI rats.  Glutamine treatment also reduces muscle atrophy in 
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the soleus muscle, but not the extensor digitorum longus (EDL).  In untreated rats the 
soleus muscle accounted for significantly (p<0.001) less of the percentage of total body 
weight than the soleus muscle from glutamine treated rats.  Finally, SCI rats with 
preserved functional abilities displayed a significantly better preserved MyHC profile 
compared to untreated SCI rats.  In the soleus healthy rats contain 94% type 1 myosin, 
treated rats maintained 68% which was significantly (p<0.001) greater than 28% 
maintained by untreated rats.  In the EDL healthy rats contain 55% type 2b myosin, 
treated rats maintained 32% which was greater than 26% type 2b myosin maintained by 
untreated rats.
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1.  Literature Review 
1.1 Skeletal Muscle Composition 
Skeletal muscle is a heterogeneous tissue that is highly organized to produce 
movement and force (Lutz and Lieber, 1999; Pette and Staron, 2000).  Each muscle is 
composed of bundles of fascicles, each containing numerous multinucleated cells called 
muscle fibers.  Every muscle fiber contains numerous protein filaments known as 
myofibrils, which are the contractile elements of skeletal muscle.  Contractile segments 
of myofibrils, termed sarcomeres, are composed of two types of myofilaments.  Thin 
filaments are mainly composed of actin molecules and thick filaments are made up of 
myosin molecules.  It is the movement of the thick and thin filaments in relation to one 
another that produce contraction (Sciote and Morris, 2000). 
 
1.1.1 Classification of skeletal muscle fiber types 
Skeletal muscle is composed of different fiber types with varying anatomical, 
molecular, metabolic, structural, and contractile properties (Pette and Vrbova, 1985; 
Pette and Staron, 2001; Pette, 2002).  Discovery of these characteristics led to a 
progression of various classification schemes.  One of the first classification schemes for 
mammalian skeletal muscle was based on fiber colors (Spangenburg and Booth, 2003).  
In 1873, due to their anatomical color and response to electrical stimulation, Ranvier 
first described slow contracting muscles as ‘red’ and fast contracting muscles as ‘white’.  
Later research found that not all red muscles were slow contracting, and expanded the 
descriptions of red and white muscle fibers also including a category of intermediate 
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fibers (Close, 1972).  This led to the development of classification schemes based on 
fiber contraction speed, and oxidative capacity (Spangenburg and Booth, 2003).  Fast 
contracting fibers have few mitochondria, low myoglobin content, high glycolytic and 
low oxidative metabolism, and are highly fatigable.  Conversely, slow contracting fibers 
have many mitochondria, a high content of myoglobin, high oxidative metabolism, and 
fatigue slowly.  Intermediate fibers fall in between white and red fibers in their 
properties (Close, 1972).    
Further studies found that in any given fiber the thick filaments contained the 
same myosin isoforms, and had a high correlation to histochemically defined fiber types 
(Termin et al., 1989; Hughes et al., 1993; Pette and Staron, 1997; Talmadge, 2000).  
Myosin is a molecule composed of light and heavy subunits.  Mammalian skeletal 
muscle contains four predominant myosin heavy chain (MyHC) isoforms, or proteins 
with similar functions and amino acid sequences, that determine the force-velocity 
characteristics of a fiber (Staron and Pette, 1986; Sciote and Morris, 2000) and the 
kinetics of its stretch-activation (Pette and Staron, 2001).   
The current classification scheme is based on the MyHC isoforms present in 
muscle fibers (Schiaffino and Reggiani, 1996; Sciote and Morris, 2000) and is described 
as the most useful method to date (Pette and Staron, 1997; Pette et al., 1999; Pette and 
Staron, 2000, 2001; Spangenburg and Booth, 2003).  Using this classification scheme, 
there are two main types of skeletal muscle fibers that are innervated by separate motor 
neurons.  They are described as fast and slow fibers (Hughes and Salinas, 1999) based 
on their force-velocity relation (Schiaffino and Reggiani, 1996) and ATPase activities 
(Hamalainen and Pette, 1995).  Fast fibers can be further broken down into three groups 
based on the MyHC isoforms that they express.  Type IIB fibers contain type IIb MyHC 
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and are the fastest contracting fibers.  They have few mitochondria, use glycolytic 
metabolism, and have a low resistance to fatigue.  Type IIA fibers contain type IIa 
MyHC and are the slowest contracting of the fast fibers.  These fibers have the highest 
oxidative capacity of the fast fibers and are relatively fatigue resistant.  In between these 
two fiber types are type IIX fibers, containing IIx MyHC and having an intermediate 
contraction speed.  The slow fibers, type I fibers, express type I MyHC and are the 
slowest contracting of all the fibers.  Type I fibers use oxidative metabolism and are 
fatigue resistant (Pette, 2001; Pette and Staron, 2001; Pette, 2002; Spangenburg and 
Booth, 2003).  Each of these four ‘pure’ fiber types express only one isoform of MyHC 
(Pette et al., 1999; Staron et al., 1999; Bobinac et al., 2000; Pette and Staron, 2000; 
Talmadge, 2000; Pette and Staron, 2001) and are found in muscles with specific 
functions.  For example, muscles containing mainly type I fibers are used for an 
antigravity function and sustained locomotor activity.  Muscles containing mainly type 
IIX and IIB fibers are specialized for short-duration, high output power activities such as 
sprinting or weightlifting, and IIA fibers are specialized for continuous contractions such 
as during long distance running (Jakubiec-Puka et al., 1999; Baldwin and Haddad, 
2002).  Nonetheless, it has been proposed that a new fiber type classification system 
may soon be determined according to genomic nomenclature (Spangenburg and Booth, 
2003).   
  
1.1.2  Myosin 
Myosins form a superfamily of proteins with structurally similar head domains, 
but structurally distinct tail domains.  The first classification scheme grouped myosins 
into two classes based on whether they contained one or two head domains.  However, 
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as new myosins were identified, myosins were classified into seven distinct groups 
based on their structurally distinct tail domain structures (Cheney et al., 1993).  
Sarcomeric myosins are categorized as class II myosins (Cheney et al., 1993; Moss et 
al., 1995; Schiaffino and Reggiani, 1996) and contain two heads and a long tail.  There 
are six other major classes of myosin proteins all containing one head and structurally 
distinct tail domain structures (Cheney et al., 1993).  
Sarcomeric myosins are hexomeric molecules composed of two heavy chains, 
each containing a head and a tail, and  two essential (alkali) light chains, and two 
regulatory (phosphorylatable) light chains (Schiaffino and Reggiani, 1994; Moss et al., 
1995; Schiaffino and Reggiani, 1996; Pette and Staron, 1997; Weiss et al., 1999; Pette 
and Staron, 2000; Pette, 2002).  Barany (1967) was the first to show that contractile 
properties were correlated with myosin isoforms and were a property of ATPase activity.  
Since then, others have shown that MyHCs determine ATPase activity (Staron and Pette, 
1986; Fauteck and Kandarian, 1995; Weiss et al., 1999) and are correlated with velocity 
of shortening (Reiser et al., 1985; Schiaffino et al., 1989; Moss et al., 1995; Jakubiec-
Puka et al., 1999; Pette and Staron, 2000; Talmadge, 2000; Pette and Staron, 2001).  
Although both MyHCs and myosin light chains both contribute to the maximum velocity 
of shortening, the alkali myosin light chain isoforms do not contribute to ATP 
consumption or tension development (Schiaffino and Reggiani, 1994; Pette and Staron, 
1997).  Therefore, it is the MyHCs that are responsible for the major functional 
differences between myosin isoforms (Weiss et al., 1999) and that determine skeletal 
muscle properties and fiber types (Bandman, 1999; Pette and Staron, 2000; Talmadge, 
2000).   
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1.1.3 Mammalian myosin heavy chain isoforms 
There are four major MyHC isoforms in the trunk and limb muscles of mature, 
small mammals.  Other skeletal MyHCs exist, but are limited to specific muscles or are 
minimally expressed (Talmadge, 2000).  The slow isoform is MyHCs I (β), and the three 
fast isoforms are know as MyHCs IIa, IIx/d, and IIb (Schiaffino et al., 1989; Schiaffino 
and Reggiani, 1994, 1996; Pette and Staron, 1997; Windisch et al., 1998; Weiss et al., 
1999; Sciote and Morris, 2000; Baldwin and Haddad, 2002; Pette, 2002).  MyHC I or Iβ 
represent the same MyHC isoform in different locations.  MyHC I is present in skeletal 
muscle and MyHC Iβ is present in cardiac muscle (Sciote and Morris, 2000).  Likewise, 
MyHC IIx and IId correspond to the same myosin isoform (Schiaffino and Reggiani, 
1994), and will be referred to MyHC IIx in the following.  The maximum contractile 
velocities of these isoforms are I<IIa<IIx<IIb (Talmadge, 2000).  For a review of the 
major MyHCs and myosin light chains found in rat skeletal muscle see Shiaffino and 
Reggiani (1994). 
 
1.2 Skeletal muscle adaptability 
Skeletal muscle fibers are dynamic with an astonishing adaptive ability (Moss et 
al., 1995; Bobinac et al., 2000; Pette, 2001; Pette and Staron, 2001).  They can adjust 
their molecular, functional, and metabolic characteristics in response to various factors 
including development, innervation, increased or decreased neuromuscular activity, 
overloading or unloading, hormones, and aging (Pette and Staron, 1997, 2001; Pette, 
2002; Fluck and Hoppeler, 2003).  While factors increasing neuromuscular activity or 
loading cause an increase in expression of slower protein isoforms and slow fibers, 
factors that decrease neuromuscular activity or loading generally cause increased 
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expression of faster protein isoforms and fiber types.  However, these changes are 
influenced by the species involved, the fiber type, and the properties of the specific 
muscle (Pette and Staron, 1997).   
Fiber type transitions are not random, but follow an orderly, sequential pattern of 
MyHC isoform transitions from I IIa IIx IIb or vice versa (Pette and Staron, 
1990, 1997, 2000; Pette, 2001; Pette and Staron, 2001).  Hybrid fibers, or fibers 
containing more than one MyHC isoform, often appear in transforming fibers and appear 
to bridge the gap between pure fiber types (Pette, 2001).  The exact molecular elements 
and mechanisms of fiber type transitions are still unclear. 
 
1.2.1 Neuron muscle interaction 
A single motoneuron and the muscle fibers that it supplies is referred to as a 
motor unit (Pette and Vrbova, 1985; Roy et al., 1991).  Sherrington (1894) was the first 
to ascertain that skeletal muscle fibers were organized as motor units.  All of the fibers 
within a motor unit show similar biochemical and histochemical properties (Pette and 
Vrbova, 1985; Schiaffino et al., 1989; Sciote and Morris, 2000; Edgerton et al., 2002).  
Type 1 fibers are controlled by postural motoneurons, while type 2 fibers are controlled 
by phasic motoneurons (Pette and Vrbova, 1985).  Thus, skeletal muscle heterogeneity is 
defined by functionally distinct motor units. 
Neuromuscular activity is defined as the combination of electrical activity and 
mechanical loading that a muscle receives (Talmadge, 2000; Edgerton et al., 2002).  It is 
widely agreed upon that neuromuscular activity or motor innervation is one of the most 
important factors for determining skeletal muscle phenotype, protein expression, and 
contractile properties (Buller et al., 1960; Buller et al., 1969; Samaha et al., 1970; Pette 
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and Vrbova, 1985; Pette and Staron, 1997; Gundersen, 1998; Jakubiec-Puka et al., 1999; 
Pette and Staron, 2000; Fluck and Hoppeler, 2003).  The importance of the nerve in 
determining skeletal muscle properties and MyHC phenotype has been shown by cross-
reinnervation studies, electrical innervation studies and denervation experiments (Esser 
et al., 1993; Huey and Bodine, 1998).   
Cross-reinnervation experiments have shown that neuronal activity can change 
muscle fiber phenotypes and MyHC expression (Bandman, 1999).  A slow muscle 
reinnervated by a fast nerve results in the slow muscle becoming faster and a fast muscle 
reinnervated by a slow nerve results in the fast muscle becoming slower (Buller et al., 
1960; Guth, 1968; Buller et al., 1969; Samaha et al., 1970; Pette and Vrbova, 1985; Pette 
and Staron, 1997, 2000).  Similarly, electrical stimulation experiments, both low and 
high frequency, cause changes in muscle phenotype via firing frequency and activation 
pattern (Pette and Staron, 1997, 2000; Fluck and Hoppeler, 2003).  Denervation studies 
have shown that a lack of innervation causes fast muscles to become slower and slow 
muscles to become faster (Pette and Staron, 2000).   
 
1.2.2 Decreased neuromuscular activity and mechanical unloading 
There are several different models of decreased neuromuscular activity and 
mechanical loading including denervation, spinalization, immobilization, tenotomy, 
microgravity, and hindlimb suspension.  Nonetheless, all of these models have similar 
outcomes (Pette and Staron, 1997, 2000; Pette, 2002).  Models of reduced neural input 
cause slow muscles to become faster and fast muscles to become slower.  For example, 
in the soleus, a slow muscle, there is a decreased expression of MyHC I, and increased 
expression of the fast MyHC isoforms (Jakubiec-Puka et al., 1990; Roy et al., 1991; 
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Pette and Staron, 1997; Huey and Bodine, 1998; Talmadge, 2000; Pette and Staron, 
2001).  In the extensor digitorum longus (EDL), a fast muscle, there is increased 
expression of slower MyHC isoforms and decreased expression of the faster MyHC 
isoforms (Jakubiec-Puka et al., 1999; Bobinac et al., 2000). 
 
1.3  Spinal Cord Injury 
In Canada, there are approximately 1,050 people who receive spinal cord injuries 
(SCI) every year.  Currently about 40,000 individuals are living with a SCI 
(http://www.rickhansen.com/Foundation/foundation_scilinks.htm).  SCIs are dynamic 
and undergo continuous changes during their first few hours, days, and even weeks after 
the injury.  Spinal cord lesions increase in size over four weeks, although within three 
days the lesion can be divided into an area of tissue destruction with an area of edema 
surrounding it (Zhang et al., 1997).  SCI has been determined to take place in two 
phases.  A primary phase of mechanical injury followed by a secondary phase of further 
damage caused by the mechanical injury (reviewed by Tator and Fehlings, 1991; Sekhon 
and Fehlings, 2001; Dumont et al., 2001). 
 
1.3.1 Primary Injury 
Primary SCI is the mechanical trauma to the spinal cord resulting in tissue 
necrosis and loss of function (Sandler and Tator, 1976; Anderson and Hall, 1993).  
Mechanisms of primary injury may include impact with continuing compression, impact 
with transient compression only, distraction, or laceration/transection (Dumont et al., 
2001).  Primary injury principally damages the central grey matter and causes cell death 
at the site of the lesion, but does little harm to the surrounding white matter (reviewed in 
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Dumont et al., 2001a; Profyris et al., 2004).  However, following the primary injury 
specific molecular and cellular events take place within minutes and continue for days to 
weeks.  These events lead to white matter damage and the spread of injury and  are 
called secondary mechanisms (reviewed in Schwab and Bartholdi, 1996; Dumont et al., 
2001a; Tator and Koyanagi, 1997).   
 
1.3.2 Secondary Injury 
Secondary injury occurs in response to the primary injury and leads to further 
damage and additional cell death (reviewed in Dusart and Schwab, 1994; Hutchinson et 
al., 2001; Sekhon and Fehlings, 2001; Schultke et al., 2003).  The extent of secondary 
injury determines the outcome of the injury (Dumont et al., 2001a). Various 
pathochemical and pathophysiological mechanisms contribute to secondary injury 
(Anderson and Hall, 1993).  These include hemorrhage, ischemia, edema, axonal and 
neuronal necrosis, phospholipid hydrolysis, free radical formation, excitotoxins, 
inflammation, demyelination, cyst formation, and scar tissue development (reviewed in 
Tator and Fehlings, 1991; Schwab and Bartholdi, 1996; Profyris et al., 2004).  Of these 
mechanisms glutamate excitotoxicity, oxidative stress, and inflammation play a major 
role in secondary processes. 
 
1.3.2.1  Excitotoxicity 
A major secondary mechanism is disruption in blood flow.  Hemorrhage, 
vasoconstriction and a disruption of venous drainage all contribute (Sandler and Tator, 
1976; see Tator, 1995; Schwab and Bartholdi, 1996; Juurlink and Paterson, 1998; 
Dumont et al., 2001a).  A disruption in blood flow leads to ischemia, which causes 
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decreased ATP, and depolarization of cell membranes.  These events lead to a massive 
release of glutamate, one of the excitatory neurotransmitters of the central nervous 
system, which accumulates producing direct damage to the spinal cord.  Additionally, 
released glutamate binds to ionotropic receptors leading to calcium and sodium influx 
into the cell.  Calcium overload activates enzymes leading to an increase in free radical 
production and oxidative stress (reviewed in Azbill et al., 1997; Juurlink and Paterson, 
1998; Dumont et al., 2001a).   
 
1.3.2.2.  Oxidative stress 
Oxidative stress is a condition in which strong oxidant production outweighs a 
cells scavenging capabilities.  Oxidative stress is often associated with inflammation and 
tissue damage, and has been implicated in various clinical conditions (Christman et al., 
1998; Christman et al., 2000; Juurlink, 2001).  There is general agreement that oxidative 
stress is a central factor in the secondary injury process and that it leads to increased 
damage to the brain and spinal cord following trauma (reviewed in Juurlink and 
Paterson, 1998; Dumont et al., 2001a). 
The production of free radicals such as reactive oxygen and nitrogen species 
(ROS and RNS respectively) are harmful because they contain an unpaired electron in 
the outer orbital which makes the compound unstable.  The free electrons enable the 
reactive species to bind to lipids, proteins, DNA, and RNA causing cell injury and tissue 
dysfunction (Azbill et al., 1997; Lovat and Preiser, 2003).  Common reactive species 
include superoxide, hydroxyl radical, nitric oxide, singlet oxygen, hydrogen peroxide, 
peroxynitrite, and hypochlorite (reviewed in Azbill et al., 1997; Juurlink and Paterson, 
1998).  Under normal conditions the cell contains defenses to effectively scavenge 
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reactive species; however, if oxidative stress overwhelms the defense networks then 
cellular damage and cell death results (reviewed in Valencia et al., 2002). 
Oxidative stress is also deleterious because it feeds into a cycle promoting glutamate 
excitotoxicity, rises in intracellular Ca2+, ATP depletion, and a further increase in 
oxidative stress (Juurlink and Paterson, 1998).  Additionally, oxidative stress is thought 
to be harmful as it activates proinflammatory genes leading to inflammation and 
increased functional losses (Bethea et al., 1998; reviewed in Profyris et al., 2004).  It is 
widely agreed upon that interventions should be aimed at reducing secondary injury in 
order to obtain improved functional outcome.  
 
1.4   The role of glutamine and glutathione 
1.4.1  Glutamine 
Glutamine (Figure 1) is the most abundant free amino acid in the blood stream 
and in the body (see Lacey and Wilmore, 1990; Calder and Newsholme, 2002; Mates et 
al., 2002; Roth et al., 2002; Valencia et al., 2002).  It has a molecular weight of 146.15 
and is composed of 41.09% carbon, 32.84% oxygen, 19.17% nitrogen, and 6.90% 
hydrogen.  Glutamine contains two amines, an α-amino group, and a terminal amide 
group.  Glutamine has many diverse functions in humans, animals, and cultured cells 
(reviewed in Lacey and Wilmore, 1990).  These include fuel and essential metabolic 
precursor for rapidly dividing cells (Newsholme, 2001; Watford, 2001; Wilmore, 2001; 
Mates et al., 2002; Tapiero et al., 2002; Oehler and Roth, 2003), carbon metabolism 
(Tapiero et al., 2002), protein synthesis (Mates et al., 2002; Tapiero et al., 2002), 
glucose homeostasis (Tapiero et al., 2002), and glutathione homeostasis (Watford, 2001; 
Mates et al., 2002; Tapiero et al., 2002). 
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Figure 1.  Structure of L-Glutamine (modified from Calder and Newholme, 2002).  
 13 
Under normal circumstances glutamine is considered to be a nonessential amino 
acid (Calder and Newsholme, 2002).  However, under certain circumstances where its 
consumption exceeds its synthesis, it is thought to become a conditionally essential 
amino acid (Amores-Sanchez and Medina, 1999; Newsholme, 2001; Watford, 2001; 
Tapiero et al., 2002; Kelly and Wischmeyer, 2003; Preiser and Wernerman, 2003).  Such 
situations include major trauma or surgery, sepsis, bone marrow transplantation, intense 
chemotherapy or radiotherapy (reviewed in Valencia et al., 2001; Tapiero et al., 2002; 
Kelly and Wischmeyer, 2003).  This observation has lead to the clinical use of glutamine 
in critically ill and post operative patients (reviewed in Lacey and Wilmore, 1990).  
Various studies have shown a beneficial effect of glutamine administration in improving 
long term survival and outcome (Lacey and Wilmore, 1990; Amores-Sanchez and 
Medina, 1999; Newsholme, 2001; Wernerman, 2003), decreasing hospital stay 
(reviewed in Wilmore, 2001), and attenuating oxidative stress (reviewed in Amores-
Sanchez and Medina, 1999; Kelly and Wischmeyer, 2003; Lovat and Preiser, 2003).  
Furthermore, glutamine administration has also been shown to decrease muscle 
glutamine breakdown and enhance muscle protein synthesis (see Calder and 
Newsholme, 2002).  Importantly, glutamine administration in humans has been shown to 
be safe with no harmful side effects (see Lacey and Wilmore, 1990; Garlick, 2001; 
Wilmore, 2001; Kelly and Wischmeyer, 2003). 
Glutamine administration is beneficial following trauma in a number of ways.  
First, glutamine administration helps to maintain immune function (Newsholme, 2001; 
Watford, 2001; Mates et al., 2002).  The carbon skeleton of glutamine can be used for 
glucose production and nucleic acid synthesis (Mates et al., 2002; Tapiero et al., 2002).  
These two factors are important for ensuring replication of immune cells.  Secondly, 
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glutamine can be converted to glutamate by glutaminase.  Glutamate dehydrogenase 
then removes an amino group and oxidizes glutamate to produce alpha-ketoglutarate 
which enters the Krebs cycle and acts to increase ATP synthesis.  Finally, glutamine, via 
glutamate, is important for glutathione synthesis (Zubay et al., 1995). 
 
1.4.2  Glutathione 
Glutathione, L-γglutamyl-L-cysteinylglycine, is a tripeptide composed of 
glutamate, cysteine, and glycine (Figure 2).  It is synthesized in two enzyme-catalyzed 
steps via γ-glutamylcysteine synthase (reaction 1), and glutathione synthase (reaction 2) 
(Meister and Anderson, 1983; Meister et al., 1986).   
1) L-glutamate + L-cysteine + ATP ↔ L-γ-glutamyl-L-cysteine + ADP +Pi 
2) L-γ-glutamyl-L-cysteine + ATP + glycine ↔ glutathione + ADP +Pi 
Glutathione is the most abundant intracellular thiol (Lucas et al., 1998; Lucas et al., 
2002), and serves to protect the cell from free radicals, reactive oxygen intermediates, 
and other toxic compounds (see Meister et al., 1986; Denno et al., 1996; Thorburne and 
Juurlink, 1996; Cooper and Kristal, 1997; Lucas et al., 1998; Amores-Sanchez and 
Medina, 1999; Prem et al., 1999; Lucas et al., 2002; Flaring et al., 2003; Johnson, 2003; 
Oehler and Roth, 2003).  Glutathione acts as an electron donor to scavenge strong 
oxidants thereby reducing oxidative stress (reviewed in Juurlink, 1999).  Glutathione 
(GSH) can reduce reactive oxygen species or oxidized proteins by donating electrons to 
produce oxidized glutathione (GSSG) and water via glutathione peroxidase.  The 
oxidized glutathione can then be reduced by glutathione disulfide reductase using 
NADPH as an electron donor (see Meister and Anderson, 1983; Cooper and Kristal, 
1997; Juurlink and Paterson, 1998; Amores-Sanchez and Medina, 1999; Lucas et al.,  
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Figure 2.  Stucture of glutathione (after The Merck Index, 1983).
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2002).  Additionally, glutathione can stop the chain of  lipid peroxidation by reducing 
the α-tocopherol radical to α-tocopherol (see Cooper and Kristal, 1997; Juurlink, 1999). 
Following spinal cord injury there is a significant decrease in glutathione within 
one hour (Kamencic et al., 2001; Lucas et al., 2002).  Studies show that glutathione 
deficiency leads to oxidative stress and cell death in many tissues (see Meister, 1994; 
Cooper and Kristal, 1997).  It has been shown that increasing intracellular glutathione 
allows cells to scavenge strong oxidants (reviewed in Cooper and Kristal, 1997; 
Juurlink, 1999); however, glutathione had poor penetration into cells (Meister et al., 
1986; Cooper and Kristal, 1997).  Meister (1986) suggested that “it would seem that an 
ideal way of increasing the glutathione levels would be to provide a derivative of 
glutathione that is effectively transported into the cell and that after transport is rapidly 
converted to glutathione within the cell”.  Others have shown that glutamine 
administration decreases glutathione depletion and leads to better recovery following 
trauma (Prem et al., 1999; Flaring et al., 2003). It has been shown that by administering 
glutamine after spinal cord injury, 75% of basal glutathione concentration is maintained 
compared to the 50% level found in spinal cord injured rats that did not receive 
glutamine (Rigley et al., 2002).  It has also been demonstrated that by increasing 
glutathione production following spinal cord injury, there is a decrease in secondary 
injuries and an increased likelihood of regaining locomotory function in rats (Kamencic 
et al., 2001). 
 
1.4.3  From glutamine to glutathione 
Glutamine increases glutathione production in two main ways.  Both ways 
involve glutamine’s conversion to glutamate intracellularly.  The first mechanism is that 
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increased intracellular glutamate enhances the ability of the glutamate/cystine antiporter 
to bring cystine into the cell (see Amores-Sanchez and Medina, 1999).  Once inside the 
cell, one cystine molecule is converted to two molecules of cysteine (Juurlink, 1999).  
Therefore glutamine administration brings two of the three components of glutathione 
into the cell (Amores-Sanchez and Medina, 1999; Prem et al., 1999).  The second 
mechanism involves the regulatory enzyme L-glutamyl-L-cysteine ligase.  Glutathione 
inhibits L-glutamyl-L-cysteine ligase activity thereby limiting synthesis of glutathione.  
However, when intracellular glutamate levels are high the inhibition of L-glutamyl-L-
cysteine ligase, by glutathione, is ameliorated allowing for increased synthesis of 
glutathione (see Juurlink, 1999).  
 
1.5 Model system 
Two muscles from the hind limb were used to study the effect of glutamine and 
SCI on rat skeletal muscle (see figure 3).  The soleus and EDL muscles were chosen 
because both are locomotory muscles that are greatly affected by paraplegia.  
Furthermore, both muscles are supplied by nerves that originate from similar rootlets off 
the spinal cord.  The soleus is innervated by the tibial nerve which arises from the sacral 
(S) level of the spinal cord at the level of S1 and S2.  The EDL is innervated by the deep 
fibular nerve which arises from the lumbar (L) and sacral levels of the spinal cord at L5 
and S1.  Following SCI, both the soleus and the EDL experience a loss of innervation as 
well as decreased weight bearing (Kendall et al., 1993). 
The soleus and EDL were also used because they are probably the most studied pair 
in the muscle biology literature (Gutman et al., 1972; Gupta et al., 1989; Termin et al., 
1989; Esser et al., 1993; Hutchinson et al., 2001).  Both act on the ankle joint and are 
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Figure 3.  Location of EDL and soleus in the rat hindlimb.  
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similar in size.  The soleus originates on the head of the fibula and the medial border of 
the tibia, and inserts into the calcaneus via the achilles tendon.  Its action is to plantar 
flex the foot at the ankle.  The EDL originates on the lateral condyle of the femur, passes 
under the extensor retinaculum, inserting onto the middle and distal phalanges of the 
toes.  Its action is to extend the phalanges and dorsiflex the foot at the ankle (Hebel and 
Stromberg, 1976).  The soleus muscle is a slow twitch extensor (Gutmann et al., 1972; 
Gupta et al., 1989; Jakubiec-Puka et al., 1990; Esser et al., 1993).  It contains 
predominantly type 1 fibers with some expression of type 2a fibers (Carraro and Catani, 
1983; Hamalainen and Pette, 1995; Staron et al., 1999; Talmadge et al., 1999) and is 
used for postural control or sustained tonic activity (Close, 1972; Pette and Vrbova, 
1985; Baldwin and Haddad, 2002).  In contrast, the EDL is a fast twitch flexor muscle 
(Gutmann et al., 1972; Gupta et al., 1989; Jakubiec-Puka et al., 1990; Esser et al., 1993; 
Roy et al., 1996).  It contains almost entirely fast fibers including type 2x and 2b 
(Carraro and Catani, 1983; Staron et al., 1999) and is used for phasic movements (Close, 
1972). 
 
1.6  Introduction and hypothesis 
Primary spinal cord injury (SCI) results from direct physical deformation of the 
spinal cord.  Following the initial mechanical trauma, secondary spinal cord injury is 
caused by the resulting pathochemical and pathophysiological events including oxidative 
stress and inflammation (Anderson and Hall, 1993).  Antioxidants play an important role 
in protecting cells from the damaging effects of oxidative stress, and may thereby help to 
reduce the amount of secondary damage following SCI.  Glutamine may play an 
essential role in this process (Newsholme, 2001).  Glutamine is the precursor of 
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glutathione which is an important antioxidant molecule that helps to prevent oxidative 
stress (Amores-Sanchez and Medina, 1999).  It has been shown that by administering 
glutamine after spinal cord injury, 75% of basal glutathione concentration is maintained 
compared to the 50% level found in spinal cord injured rats that did not receive 
glutamine (Rigley et al., 2002).  Also, increased glutathione production after spinal cord 
injury decreases secondary injuries and increased the likelihood of regaining locomotory 
function in rats (Kamencic et al., 2001). 
Skeletal muscle phenotype is strongly influenced by neuromuscular activity, and 
studies have shown that change in neural input affects the myosin heavy chain (MyHC) 
composition of a muscle (Roy et al., 1991; Nakamura et al., 1997; Talmadge et al., 1999; 
Talmadge, 2000; Huey et al., 2001; Hutchinson et al., 2001).  Mammalian skeletal 
muscles contain distinct muscle fiber types that are described as either slow or fast 
twitch depending on the type of myosin heavy chain (MyHC) isoforms they express.  
Neuronal disruption following spinal cord injury causes a shift in the expression of 
MyHC isoforms in rat, cat, and human fast and slow muscles (Roy et al., 1991; 
Talmadge et al., 1999; Talmadge, 2000; Huey et al., 2001).   
The hypothesis tested is that glutamine, as a precursor of glutathione, 
administration to spinal cord injured rats will lead to better functional recovery 
and a more preserved MyHC phenotype in locomotory muscles.   
 
1.7  Experimental Objectives 
To test the experimental hypothesis the following objectives were addressed. 
1.  To determine if glutamine administration following SCI will help improve 
functional outcome in the rat. 
 21 
2.  To determine if glutamine treatment helps to preserve MyHC profile in the soleus 
and EDL muscles of the rat. 
3.  To determine if there is a correlation between improved functional outcome and a 
more preserved MyHC profile. 
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2.  Methods 
2.1  Animal Surgery 
2.1.1 Animals 
Thirty male Wistar rats (Charles River Laboratories, Wilmington, MA) were 
obtained 11 weeks of age at 238 to 351g for this study.  Upon arrival animals were 
acclimatized for one week before surgery.  Rats received standard rat chow and water ad 
libitum and were kept in a 12 hour light/dark cycle and 25ºC temperature controlled 
conditions.  Following surgery, at weekly intervals, rats were weighed and behavioral 
testing was done.  At six weeks post surgery the animals were killed by intracardiac 
perfusion (see section 2.3.1 for full details).  All experiments were performed following 
the guidelines of the Canadian Council on Animal Care (Canadian Council on Animal 
Care, 1510-130 Albert Street, Ottawa ON Canada K1P 5G4, http://www.ccac.ca). 
 
2.1.2 Groups and Treatments 
One group (n=8) contained healthy animals that did not undergo treatment of any 
kind.  The second group (n=8) consisted of rats that received sham operations of 
laminectomies only.  The third group (n=7) received SCI, but did not receive treatment.  
Finally, the experimental group (n=7) consisted of rats that received a SCI and 
glutamine injections.  Glutamine was injected intraperitoneally at a dose of 1 mmol/kg 
which was determined to be the optimal dose at site of injury to increase glutathione 
concentrations in spinal cord tissue determined by high-pressure liquid chromatography 
(Rigley et al., 2002).  The first dose of glutamine was administered one hour after 
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surgery.    This was repeated every 12 hours to maintain blood glutathione levels as 
determined by a time response curve (Rigley et al., 2002) for one week post surgery 
(Benton et al., 2000). 
 
2.1.3 Surgery 
Each rat was placed in a chamber and anesthetized with five percent halothane 
(MTC Pharmaceuticals, Cambridge, ON) mixed with pure oxygen.   Each animal was 
subsequently transferred to a table and maintained with two and a half percent 
halothane.  The animal was shaved on its dorsal surface from the area at the base of its 
skull to the lumbar region and the area sterilized with Hibitane® (Chlorhexidine, Ayerst 
Laboratories, Montreal, ON) and 70% alcohol.  A 0.05mg/kg dose of the analgesic 
Buprenorphrine® (Reckett Benckiser Pharmaceuticals Inc., Richmond, VA) was also 
injected subcutaneously.   
Each animal was placed on its ventral surface and covered with a sterile cloth so 
that only the area to be operated upon was exposed.  An incision was made from the 
fourth thoracic vertebra to the eighth thoracic vertebra in order to locate thoracic 
vertebrae five to seven.  Superficial muscles from this area were cut and retracted, while 
deeper muscles attached to the vertebrae were removed.  Then rongeurs were used to 
remove the spinal processes and laminae from these vertebrae (Figure 4B).  Parts of the 
transverse processes were also removed so that a calibrated aneurism clip (modified 
Kerr-Lougheed clip, Walsh Manufacturing, Oakville, Ontario; Figure 4A) could be 
placed extradurally around the spinal cord at the level of the sixth thoracic (T6) vertebra 
(Figure 4C).  The injury was performed at T6 in order to induce complete paraplegia 
without involving any injury to the forelimbs.  The clip exerted a 30g force for five 
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Figure 4.  SCI model.  A)  Modified Kerr-Lougheed aneurism clip.  B)  Lumbar 
vertebrae.  a= spinal process, b= lamina, c= transverse process  C)  Rat spinal cord 12 
hours after clip surgery. 
a 
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c 
B. 
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seconds before it was removed (Rivlin and Tator, 1978).  Finally the muscle and fascia 
were closed with absorbable sutures, and staples were used to seal the skin.   
Immediately following surgery, animals received a 3ml subcutaneous injection 
of Ringers solution (Presnell and Schreibman, 1997).  Rats were then placed on a hot 
water bottle, filled with hot tap water, until the rats regained consciousness.  Sham 
surgeries were performed in the same manner, except that the aneurism clip was not 
used.  Tapered doses of Buprenorphrine® were injected at 12 hour intervals for three 
days. 
 
2.1.4 Bladder Expression 
Bladder expressions were performed on the animals that underwent the spinal 
cord injury as they lost the ability to urinate.  Bladder expressions were performed 
manually by squeezing the rat’s bladders prompting them to urinate.  This was done 
three times a day until function returned, usually around two weeks, or the animal was 
killed. 
 
2.2  Behavioral Testing 
Rats were weighed and tested weekly following surgery.  
 
2.2.1 Angle Board Method 
Rats were assessed using the angle board method of Rivlin and Tator, 1977.  This 
is a behavioral task that assesses motor function by determining the maximum angle that 
a rat can maintain its position without falling off of an angled board (Figure 5).  Rats 
started off at an angle of 25º to the horizontal.  The board was then increased at five 
 26 
 
 
 
 
Figure 5.  Angle board method used to determine the maximum angle that a rat 
can maintain his position on an angled board without falling off.  Photo courtesy 
of Elizabeth Schültke. 
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degree increments until the rat could no longer maintain his position or a maximum 
angle of 55º was reached. 
 
2.2.2 BBB Score 
The Basso-Beattie-Bresnahan (BBB) open field locomotor rating scale (Basso et 
al., 1995) rates a rat’s ability to walk using a twenty-one point scale that measures 
locomotor recovery.  Each animal receives a score that reflects its ability to perform 
certain movements including movement of the three hind limb joints, sweeping motions 
with the hind limb, weight support, paw placement, fore limb- hind limb coordination, 
toe clearance, and tail position.  Scores given by two independent observers were almost 
always identical.  When there was a discrepancy in scoring, by one point, the given 
score was reached by consensus.   
On the BBB scale zero equals total paralysis or no hind limb movement, and a 
score of twenty-one signifies normal locomotion (Figure 6).  As BBB scores increase, 
rats display an increased range of movement at the hip, knee, and ankle joints until they 
are able to take occasional steps, a score of ten.  At that point, higher scores indicated 
increased frequency of stepping, weight support, proper position of the foot, hindlimb-
forelimb coordination, toe clearance, ability to keep the tail raised, and trunk stability.  
For example, a score of one indicates that there is slight movement at one or two joints, 
and a score of two indicates that a rat has extensive movement of one joint and possibly 
slight movement of another joint.  A score of three indicates extensive movement at two 
joints (Basso et al., 1995).  A rat scoring four on the BBB scale has slight movement of 
all three hindlimb joints.  Scores of five and six indicate increased movement of the 
joints, while a score of seven signifies that a rat has extensive movement at all three 
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Figure 6.  The Basso-Beattie-Bresnahan locomotor rating scale.  A) Testing is 
performed in a plastic pool for four minutes, and each animal is scored.  B) This rat 
would receive a score of zero indicating that there is no observable hindlimb movement.  
C)  A score of eight indicates that a rat displays either a sweeping movement with no 
weight support, or plantar placement of a paw without weight support.  D)  A rat 
showing occasional plantar steps with weight support, but no forelimb-hindlimb 
coordination received a score of ten.  Photo courtesy of Elizabeth Schültke. 
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hindlimb joints.  A score of eight indicates sweeping or plantar placement of the paw 
without weight support.  When a score of nine is achieved, the rat has either plantar 
placement of the paw with weight support while standing, or weight supported dorsal 
stepping but no stepping with the paw placed on its plantar surface.  A score of ten 
indicates that a rat can take occasional weight supported steps on the plantar surface of 
his paw, but that he is not displaying any forelimb-hindlimb coordination.  When a score 
of 12 is achieved rats begin to display forelimb-hindlimb coordination.  A score of 16 
implies that a rat is displaying consistent plantar stepping and forelimb-hindlimb 
coordination, and frequent toe clearance although his paw position is not parallel during 
the stepping process, he is unable to hold his tail up, and his trunk is unstable. Finally, a 
score of 21 would indicate normal locomotion.  For a more detailed description of the 
BBB locomotor rating scale, see Basso et al., 1995. 
 
2.3 Tissue Collection 
2.3.1 Perfusion 
Rats were anesthetized with five percent halothane.  An incision was made in the 
skin just below the xiphoid process.  This was extended through the abdominal muscle 
and fascia along the ribs on either side to the midaxillary line.  Then, the diaphragm was 
cut away from the ventral thoracic wall allowing the incision to be extended along the 
midaxillary line rostrally so that the entire ventral thoracic wall could be reflected 
upward exposing the heart.  A blunt end intravenous needle was used to puncture the left 
ventricle allowing it to enter the aorta where it was held in place with hemostats.  After  
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opening the right atrium to allow the draining of blood, a cold, non-heparinized, saline 
drip was attached to the intravenous needle and allowed to start dripping.  When all of 
the blood had been drained from the rat, the intravenous drip was stopped and removed.  
At this time both the right and left hind legs were removed from the animal.  
Subsequently, the rat was perfused with four percent paraformaldehyde for other studies. 
 
2.3.2 Collection of Skeletal Muscle 
EDL and soleus muscles were removed from each limb.  Each muscle was then 
weighed, and frozen in isopentane cooled in liquid nitrogen (Brumback and Leech, 
1984).  The diaphragm from several control animals was also frozen in isopentane 
cooled in liquid nitrogen for biochemical uses as a control muscle in SDS-PAGE gels. 
Tissue samples were stored at -80ºC. 
 
2.4 Separation of skeletal muscle MyHC isoforms 
Rat skeletal muscle MyHC isoforms were separated using a protocol modified 
from the methods of Talmadge and Roy, 1993.  The modifications are described in the 
following. 
 
2.4.1 Myofibril purification 
All homogenates, suspensions, and buffers were kept on ice during the following 
procedure.  Tissue was ground using a mortar and pestle in dry ice.  Tissue was then 
separated into two or more centrifuge tubes and 0.8ml of Buffer #1 (250 mM sucrose, 
100mM KCL, 5 mM EDTA, 10mM Tris-base, pH 6.8) was added to each tube.  The 
tissue was homogenized using a pestle in 1.5ml G-tube™ (Bio Plas, Inc, California) by 
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hand for an additional minute.  The sample was then spun at 6000RPM for 10 minutes at 
four ºC, as were all other centrifugations done at four ºC, and the supernatant discarded.  
The sample was re-suspended in Buffer #2 (150 mM KCL, 10 mM Tris, 0.5% Triton-X 
100, pH 6.8), homogenized for a minute, as in the preceding sentence, and then 
centrifuged at 3000RPM for three minutes.  The sample was then re-suspended in Buffer 
#2, homogenized for a minute, and then centrifuged at 3000RPM for three minutes a 
second time.  The sample was then washed in 0.8ml Buffer #3 (150 mM KCL, 10 mM 
Tris, pH 7.0), homogenized for a minute, vortexed for 20 seconds, then centrifuged at 
3000RPM for three minutes.  The sample was then washed in Buffer #3, homogenized 
for a minute, and centrifuged at 3000RPM for three minutes three additional times 
discarding supernatant each time after the sample was centrifuged.  Enough Buffer #3 
was then added until the pellet of purified myofibrils was just submerged.  The sample 
was homogenized by hand for one minute in a centrifuge tube, centrifuged for 30 
seconds, and then stored at -80ºC until electrophoresed. 
 
2.4.2 Preparation of sample to load into gel 
Muscle samples were diluted 1:1 with glycerol and then mixed with an equal 
volume of protein stock buffer (28% glycerol, 2.8% SDS, 1 M beta-mercaptoethanol, 4X 
stacking buffer, bromophenol blue).  The 4X stacking buffer had a pH value of 6.8, and 
contained TRIS base, 10%SDS, and deionized water.  Samples were contained in 1.5ml 
centrifuge tubes and placed in boiling water for five minutes.  Samples were then 
centrifuged for 45 seconds and the supernatant drawn off and the pellet discarded. 
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2.4.3 Gels for MyHC separation 
Eight percent acrylamide mini separating gels, 30% glycerol content, with five 
percent acrylamide stacking gels were used.  For the eight percent portion of the gel, 
glycerol stock (68.3%) was mixed with premixed 40% acrylamide (Bio-Rad, Ontario, 
catalogue #161-0140) and 2% bis (Bio-Rad, Ontario, catalogue #161-0142).  After 4X 
separating buffer (TRIS base, 10% sodium dodecyl sulfate (SDS), deionized water, 
pH=8.8) and 1 M glycine stock was added, the mixture was degassed in a flask for 15 
minutes.  The mixture was then cooled on ice and TEMED, 1,2-DI-
(dimethylamino)ethane, and 10% ammonium persulfate (APS) were added.  The gel was 
then poured, overlaid with distilled water, and set aside to polymerize for 30-60 minutes.  
For the stacking gels 50% glycerol sock was mixed with premixed 40% acrylamide 
(Bio-Rad, Ontario, catalogue #161-0140) and 2% bis (Bio-Rad, Ontario, catalogue 
#161-0142) stock, 4X stacking buffer (as mentioned previously), 100mM EDTA, and 
10% SDS.  The mixture was degassed for 15 minutes.  During this time, the water 
overlay was removed from the separating gels which were then blotted dry with filter 
paper.  TEMED and 10% APS were added to the stacking gel which was poured on the 
separating gel and 10 well combs (0.75mm) inserted into the stacking gel.  
 
2.4.4 Gel Electrophoresis 
The Mini-PROTEAN three cell gel electrophoresis apparatus (Bio-Rad, Ontario) 
was set up and predetermined amounts, to produce optimum visualization, of prepared 
myofibril samples were loaded into gel lanes with a Hamilton syringe (Hamilton 
Company, Reno, Nevada).  A broad range SDS-PAGE molecular weight standard (Bio-
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Rad, Ontario, catalogue # 161-0317) with a marker for myosin at 200 000 daltons was 
also loaded into the gel.  The lower chamber of the apparatus was filled with lower 
running buffer (50 mM Tris base, 75 mM glycine, 0.05% SDS), and the upper chamber 
was filled with upper running buffer (0.1 M Tris base, 150 mM glycine, 0.1% SDS and 
0.1% beta-mercaptoethanol).  The entire apparatus was then placed into a walk-in 
refrigerator, four degrees Celsius, and attached to a power supply.  The gel was run at 
100 V for approximately 30 hours.  When complete, the gel was removed from the 
apparatus and rinsed with distilled water.  The gel was then stained with 0.25% 
Coomassie blue stain for 15 minutes, and then de-stained using 10% methanol and 10% 
acetic acid, until the MyHC bands were visible and the background staining was 
minimized.  Gels were then stored in 10% glycerol and subsequently wrapped in 
cellophane membrane (Bio-Rad, Ontario) and allowed to air dry for two days before 
being filed. 
 
2.5 Digital photography 
Gels were placed on a sheet of clear plastic on top of a white light source under a 
digital camera connected to a computer.  Scion Image (Frederick, Maryland, USA) was 
used to visualize pictures of the gels. 
 
2.6 Measuring density of MyHC isoforms 
Densities of MyHC isoforms were measured using Scion Image as employed by 
other researchers (Reidler, 2000; Kuscu et al., 2003).  First background staining was 
removed from the entire gel.  Next individual lanes were selected for density analysis.  
The density of each lane was then plotted as a series of peaks, and the area under each 
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peak was measured.  Finally, calculations were done to determine the relative percentage 
of each MyHC isoforms present in each lane. 
 
2.7  Statistical  analysis 
Statistical analyses were performed using GraphPad Prism 3.0 statistical 
software (GraphPad Software, San Diego, CA).  Analyses of variance (ANOVAs) were 
performed followed by Bonferroni post-hoc tests to determine where significant 
differences existed when there was a significant interaction between main effects.  
Arcsine transformations were performed where the data were expressed as percentages 
(Zar, 1999).  Linear regressions were performed to determine the correlation between 
myosin isoforms and BBB scores, as well as between myosin isoforms and angle board 
scores.  Parametric statistical tests were used to determine the significance of the BBB 
Locomotor scores as suggested by Scheff et al. (2002), and as employed by other 
researchers (Basso et al., 1995; Schultke et al., 2003).  A p-value of p<0.05 was 
considered to be statistically significant.  Values are expressed as mean and standard 
deviation (SD). 
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3.  Results 
3.1  Effect of SCI and treatment on rat weight 
3.1.1   Change in body weight 
Healthy and sham rats were not significantly (two-way ANOVA, p>0.05, Figure 
7, Table 1) different from each other at any time point.  Untreated rats were significantly 
different from sham rats at weeks one and two (p<0.05) and weeks three through to six 
(p<0.001).  Untreated rats were also significantly different than healthy rats at week two 
(p<0.05) and weeks three, four, five, and six (p<0.001); however, untreated rats were not 
significantly different (p>0.05) from healthy rats one week after surgery.  Treated rats 
were not significantly different (p>0.05) from healthy or sham rats one week after 
surgery, but did have a significantly (p<0.05) lower percent change in body weight two 
weeks after surgery.  Five weeks after surgery, the percent change in weight was not 
significantly different (p>0.05) between treated and sham rats.  Nonetheless, treated rats 
were significantly different from sham rats at weeks three (p<0.05), four (p<0.01), and 
six (p<0.05).  Treated rats were significantly different from healthy rats at weeks three 
through to six (p<0.01).  Treated and untreated rats were not significantly different from 
one another in the first four weeks after injury, but had significantly different percent 
changes in weight at week five (p<0.01), and week six (p<0.001).   
 
3.1.2   Change in skeletal muscle weight 
Soleus and EDL muscles were weighed six weeks post surgery after the animals 
were killed and the muscles excised. 
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Figure 7.  Effect of glutamine treatment on the change in percent body weight relative 
to baseline weight at the time of surgery.  During the first week following surgery both 
treated and untreated rats experienced weight loss.  Within the next five weeks, all 
groups of rats gained weight although treated and untreated rats weighed less than 
healthy and sham rats. For treated and untreated groups n= 7, for healthy and sham 
groups n= 8.  Each bar equals mean and SD. 
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Group Week Treated Sham Healthy 
Untreated 1 NS p<0.05 NS 
 2 NS p<0.05 p<0.05 
 3 NS p<0.001 p<0.001 
 4 NS p<0.001 p<0.001 
 5 p<0.01 p<0.001 p<0.001 
 6 p<0.001 p<0.001 p<0.001 
Treated 1  NS NS 
 2  p<0.05 p<0.05 
 3  p<0.05 p<0.01 
 4  p<0.01 p<0.01 
 5  NS p<0.01 
 6  p<0.05 p<0.01 
Sham 1   NS 
 2   NS 
 3   NS 
 4   NS 
 5   NS 
 6   NS 
 
 
Table 1.  Significant differences in percent change in body weight of treated, untreated, 
healthy, and sham rats week one through to six.  
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                  3.1.2.1  Soleus  
 
At six weeks post surgery the soleus muscles from untreated rats weighed 
significantly less (one-way ANOVA, X=0.0575 ± 0.0069, p<0.001) than all other groups 
(Figure 8).  In rats treated with glutamine, the soleus muscles made up a significantly 
(X=0.0752 ± 0.0063, p<0.001) greater percentage of body weight compared to untreated 
rats.  However, the soleus muscles from treated rats made up a significantly lower 
percentage of body weight compared to healthy (X=0.0935 ± 0.0084, p<0.001) and 
sham (X=0.0883 ± 0.0086, p<0.05) rats.  Healthy and sham animals were not 
significantly (p>0.05) different from one another. 
 
3.1.2.2   EDL 
At six weeks post surgery, the EDL percentage of body weight was not 
significantly (one-way ANOVA, p>0.05, Figure 9) different between any of the four 
groups. 
 
3.2  Behavioral analysis of hind limb strength and locomotor recovery 
Behavioral analysis was performed weekly post surgery to determine hindlimb 
strength and locomotor recovery outcome. 
 
3.2.1  Angle board method 
One-way ANOVAs with Bonferroni post-tests were performed for each week.  
Healthy and sham groups of rats were able to maintain an angle of 55º, the upper limit of 
the measurement, throughout the six weeks and were not significantly (p>0.05) different 
from one another at any time point.  Untreated rats were unable to maintain a minimum 
 39 
         
Un trea ted Treated ShamHea lthy
0.000
0.025
0.050
0.075
0.100
Untreated
Treated
Sham
Healthy
p
e
r
c
e
n
t
 
o
f
 
b
o
d
y
 
w
e
i
g
h
t
 
   Untreated  Treated    Sham     Healthy 
 
Figure 8.  Soleus muscle as percentage of body weight.  Soleus muscles from week six 
of glutamine treated animals maintain a greater percentage of body weight than 
untreated animals.  For treated and untreated groups n=7, for healthy and sham groups 
n=8.  Each bar equals mean and SD.
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Figure 9.  EDL muscle as percentage of body weight.  EDL percentage of body weight 
is similar for all groups at six weeks post surgery.  For treated and untreated groups n=7, 
for healthy and sham groups n=8.  Each bar equals mean and SD. 
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angle of 25º for the first two weeks post surgery.  All rats unable to maintain a minimum 
angle of 25º were given a score of 20.  In the following weeks untreated rats were able to 
maintain mean angles ± SD of 11.43 ± 14.35, 12.86 ± 16.29, 12.86 ± 16.29, 20.71 ± 
14.56 at weeks three, four, five, and six respectively (Figure 10).  Treated rats started 
showing signs of returning hind limb strength as soon as the first week post surgery.  For 
weeks one through six the means and SDs of this group were as follows 5.00 ± 13.23, 
10.00 ± 18.03, 32.14 ± 9.06, 36.43 ± 8.52, 35.71 ± 8.53, 36.43 ± 7.48 (Figure 10).  
Untreated and treated rats were not significantly different at weeks one, two, but were 
significantly different at weeks three, four, five (p<0.001), and six (p<0.01).  Untreated 
and treated groups were significantly (p<0.001) different from healthy and sham groups 
at all time points.   
 
3.2.2  BBB score 
One-way ANOVAs with Bonferroni post-tests were performed for each week.  
Healthy and sham groups of rats received consistent scores of 21 throughout the study 
indicating that they had normal locomotion.  Treated and untreated groups had BBB 
scores significantly (one-way ANOVA, p<0.001) lower than healthy and sham groups at 
all time points.  Untreated rats mean BBB scores were significantly lower than those of 
treated rats at one week (p<0.01) and weeks two through to six (p<0.001) post surgery.  
Untreated rats scores ± SD during weeks one to six respectively are as follows 0.43 ± 
0.79, 2.43 ± 2.44, 1.71 ± 2.81, 2.86 ± 2.91, 3.43 ± 3.05, and 2.86 ± 2.27.  Treated rats 
received scores ± SD of 4.29 ± 3.73, 9.43 ± 3.05, 8.57 ± 2.82, 9.29 ± 3.20, 9.57 ± 3.31, 
and 9.57 ± 3.31 throughout weeks one to six respectively (Figure 11).   
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Figure 10.  Weekly angle board scores of rats for six weeks.  Glutamine treated rats 
were able to maintain greater angles on an angle board than untreated rats.  Untreated 
rats were not able to maintain their positions on an angle board the first two weeks post 
surgery.  For treated and untreated groups n=7, for healthy and sham groups n=8.  Each 
bar equals mean and SD. 
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Figure 11.  Weekly BBB scores of rats for six weeks.  Glutamine treated rats 
received higher BBB scores than untreated rats at all time points.  For treated and 
untreated groups n=7, for healthy and sham groups n=8.  Each bar equals mean and 
SD. 
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3.3  Effect of SCI and treatment on rat MyHC isoforms 
3.3.1   Soleus 
Table 2A displays the mean and SDs of MyHC isoforms as a percent of the total 
myosin for the four groups.  A two-way ANOVA comparing MyHC isoforms and 
percentage of total myosin for the four different groups found that a significant 
(p<0.0001) interaction took place between the treatment groups and MyHC isoforms 
expressed in the soleus muscle.  Bonferroni post-tests were performed to determine 
where the significant differences occurred (Table 2B).  Glutamine treated rats had a 
more preserved MyHC phenotype than untreated rats.  See Figures 12A, 12B and 12C 
for pictures of SDS-PAGE of the MyHC isoforms present in the soleus muscle of the 
various groups.  Note that there are different sequences of treatment groups in each set 
of pictures.  The data was presented in this way because each set of pictures are from the 
same gel and the samples were run in the order depicted.  See section 4.3.3 for a 
discussion regarding differences in MyHC isoform distribution in diaphragm samples. 
 
3.3.2   EDL 
Table 3A displays the mean and SDs for the various groups.  A two-way 
ANOVA comparing MyHC isoforms and percentage of total myosin for the four 
different groups found that a significant (p<0.0001) interaction took place between the 
treatment groups and MyHC isoforms expressed in the EDL muscle.  Bonferroni post-
tests were performed to determine where the significant differences occurred (Table 3B).  
Healthy rats were not significantly (p>0.05) different compared to rats from the sham 
group.  Untreated rats did not express any significant (p>0.05) differences in the  
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Figure 12.  Pictures of SDS-PAGE gels showing rat MyHCs from soleus and EDL 
muscles of various treatment groups.  Each group of pictures was run in the same gel.  
Molecular weight markers and diaphragm samples were run in every gel.  The molecular 
weight marker contained two different isoforms of myosin from rabbit skeletal muscle.  
Note that myosin samples from the diaphragm contain all four MyHCs.  The slowest 
migrating band, highest band on the gel, represents MyHC 2a.  Below it is MyHC 2x, 
followed by MyHC 2b, and the fastest migrating band, lowest band on gel, is MyHC 1.  
A)  Picture showing that rat diaphragm lines up with the molecular weight marker at 
200,000 daltons.  B) Myosin from the soleus muscle.  Myosin from healthy animals 
displays predominantly type 1 MyHC, with some type 2a MyHC.  Conversely, myosin 
from untreated rats shows much less type 1 MyHC, and also expresses higher levels of 
2a and 2x MyHCs.  C) Myosin from the soleus muscle.  Myosin from rats treated with 
glutamine displays a MyHC profile similar to that of untreated rats, but displays more 
type 1 MyHC compared to type 2a or 2x MyHCs.  D)  Myosin from the EDL muscle.  
Healthy rats display the greatest expression of type 2b MyHC, with some type 2x, and 
less 2a MyHC.  Untreated rats show a decreased expression of 2b MyHc and an 
increased expression of 2x MyHC.  E)  Myosin from the EDL muscle.  Rats treated with 
glutamine have an increased expression of 2b MyHC and a decreased expression of 2x 
MyHC compared to untreated rats.  MW= molecular weight marker, D= diaphragm, H= 
healthy rat, UT= untreated rat, T= treated rat. 
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A. 
Soleus                     Percent of total myosin 
Group n 2a 2x 2b 1 
Untreated 7 33.90 ± 6.90 38.33 ± 9.31 0.09 ± 0.23 27.69 ± 5.69 
Treated 7 15.01 ± 7.49 16.54 ± 16.71 0.57 ± 1.47 67.87 ± 23.72 
Sham 8 1.06 ± 2.10 0.56 ± 1.59 0.00 ± 0.00 98.38 ± 3.05 
Healthy 8 5.11 ± 4.86 0.90 ± 1.60 0.00 ± 0.00 93.99 ± 5.66 
 
B. 
 
 
Table 2.  Soleus MyHC isoform percentage of total myosin at six weeks post surgery.  
A)  Values shown are mean and SD.  B)  Significant differences in MyHC isoforms in 
the soleus of treated, untreated, sham, and healthy groups.  There is a significant 
interaction (two-way ANOVA, p<0.0001) between treatment group and MyHC isoform 
expression; therefore, Bonferroni posttests were performed.  Glutamine treated rats 
display a more preserved myosin phenotype in the soleus muscle than untreated rats.   
 
 
Group MyHC Treated Sham Healthy 
Untreated 1 p<0.001 p<0.001 p<0.001 
 2a p<0.05 p<0.001 p<0.001 
 2x p<0.01 p<0.001 p<0.001 
 2b NS NS NS 
Treated 1  p<0.001 p<0.01 
 2a  p<0.05 NS 
 2x  p<0.05 p<0.01 
 2b  NS NS 
Sham 1   p<0.05 
 2a   p<0.05 
 2x   NS 
 2b   NS 
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A. 
EDL                     Percent of total myosin 
Group n 2a 2x 2b 1 
Untreated 7 0.36 ± 0.96 73.50 ± 7.37 25.97 ± 7.34 0.17 ± 0.53 
Treated 7 2.21 ± 4.01 65.51 ± 20.52 31.96 ± 17.72 0.33 ± 0.87 
Sham 8 13.57 ± 8.13 31.69 ± 5.51 51.22 ± 9.14 3.52 ± 4.62 
Healthy 8 11.20 ± 3.11 31.46 ± 7.72 54.99 ± 9.40 2.36 ± 2.71 
 
B. 
 
Group MyHC Treated Sham Healthy 
Untreated 1 NS NS NS 
 2a NS p<0.001 p<0.001 
 2x NS p<0.001 p<0.001 
 2b NS p<0.001 p<0.001 
Treated 1  NS NS 
 2a  p<0.01 p<0.01 
 2x  p<0.001 p<0.001 
 2b  p<0.05 p<0.01 
Sham 1   NS 
 2a   NS 
 2x   NS 
 2b   NS 
 
 
Table 3.   EDL MyHC isoform percentage of total myosin at six weeks post surgery.   
A)  Values shown are mean and SD.  B)  Significant differences in MyHC isoforms in 
the EDL of treated, untreated, sham, and healthy groups.  There is a significant (two-
way ANOVA, p<0.0001) interaction between treatment group and MyHC expression.  
Bonferroni posttests were performed to determine where significant differences exist.  
Treated and untreated rats are not different from each other, nor are healthy and sham 
rats.  However, both treated and untreated rats show significant differences in MyHC 
expression compared to healthy and sham rats.  
 48 
percentages of MyHC isoforms expressed compared to treated rats.  However, there 
were significant differences in MyHC percentage of total myosin between 
treated/untreated, and healthy/sham groups in the expression of type 2 MyHCs.  More 
specifically, treated and untreated rats have less 2a and 2b MyHCs and more type 2x 
MyHC than healthy and sham rats.  No significant difference existed between type 1 
MyHCs.  See Figures 12D and 12E for pictures of SDS-PAGE of the MyHC isoforms 
present in the EDL muscles of the various groups. 
 
3.4  Correlation between behavioral scores and MyHC isoform expression 
Linear regressions were performed to determine if improved behavioral scores 
were correlated to more preserved MyHC expression.  For example, in the soleus muscle 
which contains a majority of type 1 MyHCs, linear regressions were performed to see if 
better behavioral scores were related to a greater percentage of type 1 MyHC in the 
soleus muscle.  Alternatively, in the EDL which contains mainly type 2b MyHCs a 
linear regression analysis was performed to see if better behavioral scores were 
accompanied by greater amounts of type 2b MyHC expression. 
Linear regressions were performed comparing the percentage of type 1 MyHC 
present in rat soleus muscle to the six week angle board scores, and the six week BBB 
scores attained by all rats (n=30).  Similarly, linear regressions were performed 
comparing the percentage of type 2b MyHCs present in rat EDL muscles to the six week 
angle board, and six week BBB scores attained by these same rats to see if there were 
any correlations between these parameters.  The data from these results show that better 
locomotion and greater hindlimb strength are also related to a more preserved MyHC 
phenotype. 
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3.4.1 Angle board method 
There was a significant (linear regression, r2= 0.8686, p<0.0001, Figure 13) 
correlation between the percent of type 1 MyHC isoform present in the soleus muscle 
and angle board score received by all rats involved in the study.  Similarly, a significant 
(Linear Regression, r2= 0.6084, p<0.0001, Figure 14) correlation was found between the 
percent of type 2b MyHC isoform present in the EDL muscle and the angle board score 
received by all rats in the study. 
 
3.4.2  BBB score 
When comparing the percent of type 1 MyHC isoform present in the soleus 
muscle and the BBB scores received by rats via linear regression a significant (r2= 
0.8708, p<0.0001, Figure 15) correlation was found.  Likewise a significant (r2= 0.6290, 
p<0.0001, Figure 16) correlation was found when comparing the percent of type 2b 
MyHC isoform expressed and BBB scores achieved. 
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Figure 13.  Angle board scores are correlated to the percent of type 1 MyHC in the 
soleus muscle.  Scatter plot displaying percent of type 1 myosin of total MyHC pool 
from rat soleus muscle and angle board score achieved at six weeks for all rats involved 
in the study (p<0.0001, r²=0.8686).
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Figure 14.  Angle board scores are correlated to percent of type 2b MyHC in the EDL 
muscle.  Scatter plot displaying percent of type 2b myosin of total MyHC pool from rat 
EDL muscle and angle board scores achieved at six weeks for all rats involved in the 
study (p<0.0001, r2 = 0.6084).  
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Figure 15.  BBB scores are correlated to percent of type 1 MyHC in the soleus muscle.  
Scatter plot displaying percent of type 1 myosin of total MyHC pool from rat soleus 
muscle and six week BBB score for all rats involved in the study (p<0.0001, r²=0.8708).   
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Figure 16.  BBB score and percent of type 2b MyHC is correlated in the EDL muscle. 
Scatter plot displaying percent of type 2b myosin of total MyHC pool from rat EDL 
muscle and six week BBB score for all rats involved in the study (p<0.0001, r²=0.6290). 
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4.  Discussion 
4.1  Change in weight 
4.1.1  Body weight 
Studies have shown that rats with spinal cord injuries have a significantly lower 
body mass than control rats 15 and 30 days post injury (Talmadge et al., 1999).  This is 
due to the large decrease in weight that SCI rats experience one week after surgery 
(Huey et al., 2001).  The results of this study are in agreement with SCI rats weighing 
significantly less than healthy and sham rats.  However, a significant difference between 
treated and untreated rats was also noted with untreated rats weighing less than rats from 
the glutamine treated group. 
Glutamine treated rats may be better able to maintain weight compared to 
untreated rats following SCI.  Skeletal muscle is the most important glutamine producer 
in the body.  During states of stress and trauma, protein break down occurs in skeletal 
muscle in an effort to increase the supply of glutamine to the rest of the body (see 
Newsholme, 2001; Soeters, 2001; Wilmore, 2001; Calder and Newsholme, 2002; 
Newsholme et al., 2003).  Studies of glutamine-enriched total parenteral nutrition, 
nutrient rich fluid given by vein, after sepsis have shown increased rates of skeletal 
muscle protein synthesis and decreased rates of skeletal muscle protein degradation 
(Ardawi, 1991).  Glutamine treatment following SCI would be providing an external 
source of glutamine to the body, thereby decreasing protein degradation in skeletal 
muscle.  
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A second way that glutamine treatment may be helping to maintain weight is by 
helping to maintain innervation to the muscle.  By maintaining innervation, a degree of 
locomotion is preserved.  This is beneficial because if a muscle is not used than it 
undergoes swift atrophy.  This is particularly true for postural muscles that are 
frequently used under normal circumstances (see Baldwin and Haddad, 2002).  For 
example, the slow soleus muscle is more affected by chronic unloading than fast 
muscles such as the EDL, plantaris, tibialis anterior, and the gastrocnemius.  The soleus 
shows greater changes not only in muscle atrophy, but also in contractile properties, 
fiber type composition, and myosin content (see Pette and Starron, 1997). 
 
4.1.2  Muscle weight 
Muscle atrophy following SCI is specific for different muscles and varies 
depending on the kind of muscles.  For example, extensor muscles atrophy more than 
flexor muscles, and slow muscles atrophy more than fast muscles (see Roy et al., 1991; 
Kraemer et al., 2000).  
 
4.1.2.1  Soleus 
It has been shown that the soleus muscle from SCI rats shows significant atrophy  
(Jakubiec-Puka et al., 1999; Talmadge et al., 1999; Huey et al., 2001).  The current study 
found similar results to those listed above.  The soleus muscle, a slow extensor of the 
ankle (Gutmann et al., 1972; Gupta et al., 1989; Jakubiec-Puka et al., 1990; Esser et al., 
1993), from both treated and untreated rats in this study displayed significantly more 
atrophy compared to healthy and sham rats.  This was expected because following SCI 
rats are paraplegic and have very little, if any, use of their hindlimbs.  However, 
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treatment with glutamine made a significant difference in SCI rats such that the soleus 
atrophy was lessened compared to untreated rats.  As discussed in section 4.2, glutamine 
treated rats had significantly greater locomotor abilities and hindlimb strength.  
Increased use of the hindlimbs and hindlimb muscles, particularly postural muscles, may 
have contributed to decreased atrophy of the soleus muscle. 
 
4.1.2.2  EDL 
Unlike the soleus muscle, the EDL did not display any significant differences in 
weight between any of the groups.  While the soleus muscle is a slow twitch ankle 
extensor, the EDL is a fast twitch ankle flexor and studies of denervation and SCI have 
shown that the EDL atrophies less than the soleus (Jakubiec-Puka et al., 1990; Jakubiec-
Puka et al., 1999; Staron et al., 1999; Hutchinson et al., 2001).  In fact, Hutchinson et al. 
(2001) looked at numerous hindlimb muscles and found that following SCI the EDL was 
the only muscle that did not experience a significant decrease in muscle weight in the 
first couple of weeks following surgery.  When muscles are unloaded, during chronic 
bed rest or space flight, the primary targets for protein degradation are muscle fibers 
containing type 1 MyHC.  Notably, the EDL contains very little type 1 MyHCs 
(Baldwin and Haddad, 2002).  Additionally, as stated previously, because the EDL is not 
a postural muscle it does not atrophy to the same extent as the soleus does with 
unloading.   
Continuous muscle stretch has been shown to prevent muscle atrophy following 
disuse (Loughna et al., 1986; Roy et al., 1992; Loughna and Morgan, 1999; Sasa et al., 
2004).  Passive stretch leads to muscle growth by increasing protein synthesis although 
it does little to decrease protein degradation (Yang et al., 1997).  Studies have shown 
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that passive stretch not only contributes to increased muscle mass, but can also influence 
MyHC gene expression (Roy et al., 1992; Loughna and Morgan, 1999).  Loughna and 
Morgan (1999) showed that denervation leading to decreased type 1 and type 2a 
expression in the soleus and the gastrocnemius muscles could be decreased by 
immobilizing these muscles in a lengthened position following denervation.  In another 
study Loughna et al. (1986) used a suspension model to unload the hindlimbs of rats.  
While suspended, rats had one leg restrained in a dorsiflexed position with the EDL 
slack, while the other leg was allowed to hang freely in a plantar flexed position with the 
EDL stretched.  They found that the plantar flexed EDL atrophied to a lesser degree than 
the EDL in the dorsiflexed position.  Passive stretch was effective in reducing muscle 
atrophy by increasing protein synthesis.   
In the present study similar factors may have been responsible for preventing 
EDL muscle atrophy.  After SCI, rats pull their hindlimbs behind themselves with the 
dorsal part of their foot and toes dragging on the floor.  This passively stretches the 
EDL, but not the soleus muscle.  Rats scoring below eight on the BBB scale are not 
exhibiting plantar placement of the foot.  Furthermore, rats with a BBB score below 16 
are not displaying any toe clearance during the stepping process (Basso et al., 1995).  All 
SCI untreated rats had BBB scores below 7, and of the SCI treated rats, only one 
attained a score above 11.  Therefore, it is likely that all SCI rats were experiencing 
stretching of the EDL muscle and this could explain why there were no significant 
differences in EDL weight among any of the rats.  
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4.2  Behavioral analysis 
4.2.1  Angle board 
No significant differences were detected between treated and untreated SCI rats 
during the first two weeks post surgery.  One reason for this may have been due to the 
large standard deviations seen for the glutamine treated rats.  During the first two weeks 
after SCI there is a lot of variability among angle board scores indicating that rats are 
recovering hindlimb strength at different rates.  Another reason for no significant 
difference between SCI groups during the first two weeks is that angle board scores 
were measured starting at a minimum angle of 25 degrees.  In retrospect, the minimum 
angle measured might have been started at a lower angle.  This would have ensured that 
any slight differences between treated and untreated groups during the first two weeks 
might have been detected.  A final explanation could be that at two weeks rats had not 
recovered enough coordination or strength in their hindlimbs to enable them to maintain 
their position on the angled board. 
After two weeks, treated rats acquired significantly higher angle board scores 
than untreated rats.  However, treated rats never achieved scores as high as healthy or 
sham rats.  This indicated that glutamine administration helps maintain hindlimb 
strength, but at a reduced level.   
 
4.2.2  BBB scores 
Treated SCI rats had significantly better BBB scores than untreated rats at all 
time points in the study.  At six weeks untreated rats achieved a mean score of 2.86, 
while treated rats had a mean BBB score of 9.57.  Comparing the differences in 
locomotory function of these scores at six weeks highlights the differences between the 
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two groups.  A score of three on the BBB scale indicates that a rat has extensive 
movement of two of the three hindlimb joints, but is unable to support his weight or take 
steps.  Alternatively, a score of ten indicates that a rat has extensive movement of all 
three hindlimb joints, can support his weight, and is taking occasional steps.  
Additionally, the steps are on the plantar surface of the foot rather than on the dorsal 
surface.  However, a score of ten indicates that the rats do not display any forelimb-
hindlimb coordination (Basso et al., 1995).  In reference to angle board scores, one 
would not expect that a rat without forelimb-hindlimb coordination would be able to 
maintain as great of an angle as a healthy rat with perfect locomotory skills. 
One point of interest apparent in the BBB scores was that all rats in the SCI 
treated group obtained the same scores in week five that they did in week six.  This may 
indicate that the treated rats reached a plateau in their locomotory recovery at five 
weeks.  In a study of moderate spinal cord contusion, animals initially experience 
hindlimb paralysis but regain limited locomotor capabilities with weight bearing within 
several weeks.  Hutchinson et al. (2001) produced by a 1.1mm displacement of one 
spinal cord surface with respect to the other spinal cord surface using the Ohio State 
University impact device.  The Ohio State University impact device is an 
electromechanical impactor that is lowered down onto the spinal cord until the desired 
force is applied (Noyes, 1987).  They found that BBB scores of injured rats reached a 
plateau from three to ten weeks post injury.  It has also been found that the Functional 
Independence Measure score of humans, with a SCI below T6, will plateau at three 
months post-injury.  
 Another point of interest becomes apparent when comparing the results that 
untreated rats attained on the BBB score and the angle board method.  Specifically, 
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untreated rats had different BBB scores at all time points.  However, they did not score 
differently on the angle board during the first two weeks.  This difference could be 
explained as stated previously by not measuring angle less than 25 degrees on the angled 
board.  Nonetheless, this difference in scores between the two techniques may indicate 
that locomotor ability returns faster than hindlimb strength, or that the BBB score is 
more sensitive to small changes than the angle board method. 
 
4.3  MyHC isoform expression 
It has been shown that muscle atrophy occurring in the first week following SCI 
is not accompanied by any change in the muscles myosin isoform profile.  This implies 
that during muscle atrophy the absolute amount of myosin is decreasing and has no 
affect on the relative percentage of different MyHC isoforms.  Later however, there is 
increased expression of some MyHCs and decreased expression of other MyHCs 
depending on the muscle (Huey et al., 2001).  These fiber transitions are evident in the 
increased expression of hybrid fibers (Pette and Staron, 2000; Talmadge, 2000; Pette, 
2001; Pette and Staron, 2001). 
 
4.3.1  Soleus 
The soleus muscles of SCI rats displayed a shift in MyHC expression from slow 
type 1 MyHCs towards faster MyHC isoforms expression.  Specifically, in SCI rats there 
was an increased expression of 2a and 2x MyHC isoforms, but a decreased expression of 
type 1 MyHC compared to healthy and sham rats.  Other studies using various models of 
decreased neuromuscular activity have found similar results.  In a study of spinal cord 
transection, the soleus muscle from injured rats had an increased expression of type 2a 
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and 2x MyHCs, and a decreased expression of type 1 MyHCs (Talmadge et al., 1999).  
Huey et al. (2001) determined that after spinal cord isolation, a procedure producing 
complete neuromuscular inactivity while maintaining motoneuron-muscle connections, 
the soleus of injured rats expressed higher amounts of type 2x MyHC and lower 
amounts of type 1 MyHC.    A study of sciatic nerve crush found the same results for the 
soleus muscle (Jakubiec-Puka et al., 1990). 
There were significant differences in MyHC isoform expression found between 
glutamine treated and untreated rats.  Untreated SCI rats had significantly more 2a and 
2x MyHC isoforms and significantly less type 1 MyHC isoform expression than 
glutamine treated rats, which were able to maintain a greater level of type 1 myosin.  It 
is known that intact neural innervation and muscle activity are required for normal 
energy metabolism, muscle structure and function.  For example, changes in neural 
innervation or muscle activity can increase or decrease metabolic enzyme activity and 
cause shifts in aerobic-oxidative or anaerobic metabolism.  Furthermore, structural 
changes take place within the muscle causing sarcomeric and membrane protein isoform 
profiles to be altered.  Finally, muscle function is impacted altering contraction and 
relaxation times (Gupta et al., 1989; Pette, 2001; Pette and Staron, 2001; Pette, 2002).  
Thus, muscle fibers have the ability to transform and adjust their phenotypic profile to 
better meet functional requirements (Pette, 2001).  Therefore, if glutamine 
administration following SCI helps to maintain neural innervation and muscle activity, 
then a more preserved MyHC phenotype would be expected in the soleus muscle of the 
treated rats. 
Despite the differences in MyHC expression among rat groups, there was one 
similarity for all groups.  There were no significant differences in 2b MyHC isoform 
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expression.  This was likely the result of very little 2b MyHC expression in the soleus 
muscle. 
 
4.3.2  EDL 
Contrary to the soleus muscle, treated and untreated groups were not 
significantly different from one another.  However, the EDL of SCI rats was 
significantly different compared to healthy and sham rats.  The EDL from all SCI rats 
had significantly less type 2a and 2b MyHC isoforms, but more 2x MyHC than the EDL 
of healthy or sham rats.  Type 1 MyHCs accounted for less than five percent of total 
MyHCs and was unaffected between groups.  Thus after SCI, type 2b and some 2a 
MyHCs were replaced by slower type 2x MyHCs.  Other studies have also found that 
after SCI the EDL displays an increase in 2x MyHC (Hutchinson et al., 2001) and a 
decrease in type 2b MyHCs (Jakubiec-Puka et al., 1990; Hutchinson et al., 2001).   
These results indicate that glutamine treatment alone is not enough to help 
maintain the phenotypic profile of the EDL.  Although glutamine treatment helps to 
maintain hindlimb strength and locomotor abilities, these effects likely play a more 
important role in the maintenance of the soleus muscle.  During locomotion, slow 
twitch, postural muscles are more active than phasic muscles such as the EDL (Pette and 
Vrbova, 1985).  Furthermore, even with glutamine treatment, rats have limited recovery 
and likely do not maintain enough function where fast muscles would benefit because 
fast twitch muscles fibers are recruited for intense bursts of activity. 
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4.3.3  Diaphragm 
Rat diaphragm myosin was run as a control to visualize MyHC bands in every 
gel because it displays all four MyHC isoforms.  However, the same diaphragm myosin 
sample was not used for every gel and as a result differing amounts of various myosin 
isoforms can be visualized in the gels shown in figure 12.  The reason for the differing 
amounts of MyHC isoforms seen in different myosin samples from the diaphragm are 
due to the fact that the diaphragm has a heterogeneous fiber type distribution (Sugiura et 
al., 1992).  There are significantly more type 1 muscle fibers in the ventral costal region 
compared to the crural region of the diaphragm.  Additionally, the crural region has 
significantly more 2b fibers compared to the costal diaphragm (Metzger et al., 1985).  
Finally, in figure 12A there is an additional band below type 1 MyHC in the diaphragm 
sample.  This band is a degradation product.  Although muscle samples were stored at -
80ºC, myosin will start to degrade over an extended period of time. 
 
4.3.4  Differences in fast and slow muscle regulation 
Much research supports differing properties of fast and slow muscles, and how 
their regulation may differ.  Gutmann et al. (1972) was one of the first to note that fast 
and slow muscles react differently to denervation.  The EDL developed a prolonged 
contraction time, while the contraction time was shortened in the soleus.  It was 
subsequently observed that regulation of the same MyHC isoform may vary in different 
muscles (Jakubiec-Puka et al., 1999).  During development and regeneration, nerves 
play different roles in fast and slow muscle phenotypic profiles.  For example, fast 
nerves are not necessary for the development of fast muscles, but slow nerves are 
necessary for the development of slow muscles (see Esser et al., 1993; Huey and Bodine, 
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1998).  Finally, fast and slow muscles are activated differently during locomotion.  Slow 
muscle fibers are used to a much greater extent than are fast fibers.  Additionally, while 
fast muscles are only active during locomotion, slow muscles are active during both 
locomotion and postural maintenance (Pette and Vrbova, 1985).   
 
4.4  Correlation between behavioral scores and MyHC expression 
Angle board scores and BBB scores both had a strong correlation to the amount 
of type 1 MyHC present in the soleus muscle.  The correlation between behavioral 
scores and the amount of type 2b MyHC present in the EDL was also quite strong 
although to a lesser extent than those of the soleus.  The correlation between higher 
behavioral scores and a more preserved MyHC profile indicates that improved 
functional outcome is related to the maintenance of a muscle’s myosin profile.  This is 
particularly true for slow twitch muscles.   
For both the soleus and the EDL, BBB scores were slightly more correlated to 
MyHC profile than angle board scores.  This may suggest that locomotor recovery is a 
better indication of muscle preservation than hindlimb strength is.  Nonetheless, the 
strong correlation between behavioral scores and MyHC profile indicates that if MyHC 
phenotypic profile is being maintained, locomotion is being salvaged as well.   
 
4.5  Hypothesis validation 
It was hypothesized that intraperitoneal glutamine administration following SCI 
would improve functional outcome and hindlimb strength in rats.  Additionally, that 
improved functional outcome would be accompanied with preserved MyHC profile in 
the soleus and EDL muscles in the rat.  The hypothesis was confirmed although MyHC 
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profile was more affected in the soleus than in the EDL.  Histological analyses of the 
spinal cords from the same group of rats were carried out by Rigley et al. (2004).  They 
demonstrated that SCI rats receiving glutamine treatment had greater white matter 
sparing than untreated SCI rats (Rigley et al., 2004).  Furthermore, they found that 
intraperitoneal injections of glutamine were effective in increasing blood glutathione 
levels and maintaining them.  
Glutamine administration to SCI rats works by decreasing oxidative stress which 
increases basal glutathione levels.  As a result, there is a decrease in the amount of 
secondary spinal degeneration following the primary injury and increased tissue sparing.  
This leads to maintenance of the ‘normal’ MyHC phenotype, and preserved locomotory 
function.  Additionally, glutamine administration following SCI helps rats maintain 
body weight and skeletal muscle weight by providing ‘conditionally essential’ glutamine 
to the rats, thereby decreasing skeletal muscle protein degradation. 
 
4.6  Future directions 
Future studies could be conducted to determine how glutamine is affecting other 
properties, besides MyHC isoform profiles, of fibers.  For example, 
immunohistochemistry experiments could be carried out to determine if glutamine 
treatment has any effect on maintaining fiber size and the number of fibers present 
within a muscle.  Additionally, immunohistochemistry experiments could be used to 
determine the effect of glutamine on the hybrid fiber population of muscles; if there are 
more or less fibers expressing more than one MyHC isoform, this would determine if 
muscle phenotype is being preserved on levels besides MyHC expression in glutamine 
treated rats.   
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Another avenue that would be interesting to explore is the effect of glutamine 
administration in skeletal muscle, specifically, whether glutamine concentration is 
increased within the skeletal muscle of treated rats.  If glutamine was being maintained 
or increased in skeletal muscles there would be stronger evidence that glutamine is 
helping to preserve muscle by preventing protein breakdown rather than just through 
maintaining the muscle-neural connection. 
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